Schwab Fundamental U.S. Small Company ETF (FNDA) is a publicly traded the market company. As of May 21, 2026, FNDA trades at $35.27 with a market cap of $0 and a P/E ratio of 0.00. FNDA moved +1.94% today. Year to date, FNDA is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $0.00 to $0.00. Rallies surfaces FNDA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Emergent BioSolutions Secures FDA OK for 6-Count and 24-Count NARCAN Multipacks: Emergent BioSolutions won FDA approval for over-the-counter NARCAN Nasal Spray in new 6-count and 24-count multipacks, expanding options for high-volume naloxone distributors. EBS represents approximately 0.33% of the Schwab Fundamental U.S. Small Company ETF, which may modestly benefit from increased naloxone sales after over 85 million doses distributed.
| Metric | Value |
|---|---|
| Price | $35.27 |
| Market Cap | $0 |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $0.00 |
| 52-Week Low | $0.00 |
| Volume | 600.77K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
FNDA analyst coverage data. Average price target: $0.00.